Increased intestinal permeability in ankylosing spondylitis--primary lesion or drug effect?
We have found increased small intestinal permeability to 51Cr-ethylenediaminetetra acetate in patients with ankylosing spondylitis compared with controls. There is no significant difference between patients with ankylosing spondylitis and patients with rheumatoid arthritis taking non-steroidal anti-inflammatory drugs (NSAID). The increased intestinal permeability in ankylosing spondylitis is independent of disease activity. These findings suggest that the increased permeability is caused by NSAID treatment and is probably not a primary lesion of small bowel mucosa.
Morris
A J
AJ
Gastroenterology Unit, Glasgow Royal Infirmary.
Howden
C W
CW
Robertson
C
C
Duncan
A
A
Torley
H
H
Sturrock
R D
RD
Russell
R I
RI
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000503:physiopathology; D002860:Chromium Radioisotopes; D004492:Edetic Acid / Q000494:pharmacology; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects / Q000502:physiology*; D007421:Intestine, Small / Q000187:drug effects / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D013167:Spondylitis, Ankylosing / Q000503:physiopathology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002860:Chromium Radioisotopes; D004492:Edetic Acid